Filtered By:
Condition: Thrombosis
Drug: Pradaxa

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 508 results found since Jan 2013.

Selecting the right anticoagulant for stroke prevention in atrial fibrillation
CONCLUSIONS: Non-valvular AF patients on apixaban had lower rates of thromboembolic events than the patients on acenocumarol. This article will serve as a reminder of the positive health and financial outcomes of apixaban use, especially to those healthcare systems that are still oblivious to the decrease in economic burden and gain in quality-adjusted life years (QALY) by the long-term use of NOACS/ DOACS instead of the AVK anticoagulants.PMID:34286492 | DOI:10.26355/eurrev_202107_26241
Source: Pharmacological Reviews - July 21, 2021 Category: Drugs & Pharmacology Authors: N R Kundnani C I Rosca A Sharma A Tudor M S Rosca D D Nisulescu H S Branea V Mocanu D C Crisan D R Buzas S Morariu D F Lighezan Source Type: research

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
Conclusion: SD-W has the lowest C/U ratio among the 3 options. However, dabigatran might be considered as an alternative. GT-W is not C/U and should not currently be recommended for the routine anticoagulotherapy management of AF patients.
Source: Thrombosis Journal - July 17, 2013 Category: Hematology Authors: Léon NshimyumukizaJulie DuplantieMathieu GagnonXavier DouvilleDiane FournierCarmen LindsayMarc ParentAlain MilotYves GiguèreChristian GagnéFrançois RousseauDaniel Reinharz Source Type: research

New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Abstract Four recently introduced new oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) have been shown to be at least as efficacious and safe as warfarin for stroke prevention in patients with atrial fibrillation in their respective trials. The first three have been approved, while edoxaban is awaiting regulatory approval. Several guidelines have endorsed the approved new oral anticoagulants over warfarin because of their favourable risk-benefit ratio, low propensity for food and drug interactions, and lack of requirement for routine coagulation monitoring. In this invited review, we summarise ...
Source: Thrombosis and Haemostasis - February 20, 2014 Category: Hematology Authors: Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS Tags: Thromb Haemost Source Type: research

Left atrial appendage thrombus with resulting stroke post-RF ablation for atrial fibrillation in a patient on dabigatran.
We report the case of a patient with documentary evidence of left atrial appendage (LAA) thrombus formation and neurological sequelae post-RF ablation despite being on dabigatran. This case highlights the concern that periprocedural dabigatran may not provide adequate protection from development of LAA thrombus and that a standardised protocol will need to be developed and undergo large multicentre trials before dabigatran can be safely used for patients undergoing RF-ablation. PMID: 25551903 [PubMed - in process]
Source: Ir Med J - November 1, 2014 Category: Journals (General) Authors: Lobo R, McCann C, Hussaini A, Meany TB, Kiernan TJ Tags: Ir Med J Source Type: research

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.
CONCLUSIONS: -DOACs demonstrated at least equal efficacy to VKA in managing thrombotic risks in the elderly however bleeding patterns were distinct. In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA. Insufficient published data for apixaban, edoxaban and rivaroxaban indicates further work is needed to clarify their bleeding risks in the elderly. PMID: 25995317 [PubMed - as supplied by publisher]
Source: Circulation - May 20, 2015 Category: Cardiology Authors: Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M Tags: Circulation Source Type: research

Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
CONCLUSIONS: Regardless of clinical implications, our results can be the basis to develop local acquisition tenderings on NOACS. In Italy, a new law has been issued according to which equivalence analyses have become a mandatory prerequisite for local tenderings. PMID: 25295718 [PubMed - in process]
Source: International Journal of Clinical Pharmacology and Therapeutics - June 4, 2015 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research